Clinical Trial

Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study was a single-dose, randomized, double-blind, placebo-controlled study of SSS55 injection to evaluate the safety, tolerability, PK characteristics, immunogenicity and preliminary efficacy characteristics of single-dose SSS55 injection in healthy individuals.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-30.
Status change: Not Yet Recruiting → Recruiting 2026-02-26
Trial Details
NCT Number NCT07058779
Lead Sponsor Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions Safety Issues
Enrollment 26 participants
Start Date 2025-08-04
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-02